Investing in Innovative

cannabis Science

Emerald Health Therapeutics is a cannabis company committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis products, with an emphasis on innovation, science and product excellence.

Emerald is uniquely positioned to pursue multiple growth options with a clear focus on profitability, sustainability and value creation for its shareholders.

Investor Resources

Investor Presentation

June 17, 2021

Fact Sheet

January 7, 2021

Stock Information

Currency in CAD. Stock chart updated daily.

Our Facilities

Strongly focused on consumer preferences and production excellence, Emerald’s fully operational facilities are purposefully designed to provide defined-scale, high quality dried flower to the premium market segment and to support the development of differentiated specialty cannabis products.

Greater Vancouver

Emerald’s R&D facility in Greater Vancouver, BC, is explicitly designed, licensed and focused on the development of novel cannabinoid-based specialty products. The facility houses the new product development team with a mandate to create new intellectual property involving patents or trade secrets and is empowered to consider new concepts based on a spectrum of possibilities including formulation, delivery, bioavailability, and therapeutic capabilities, and to incorporate the attributes of “predictable action” and “Defined Dose™” to give consumers the benefit of discreet convenient consumption and reproducible outcomes in terms of rapid onset and offset of effects.

St. Eustache

Emerald’s vertically integrated 88,000 square feet indoor operation in Saint-Eustache, QC, is focused on producing premium craft cannabis products, notably under its Quebec-oriented Souvenir Brand. With standard cultivation and processing licenses, this operation is able to cultivate, sell and distribute packaged, branded cannabis products directly to provincial/territorial wholesalers and authorized private retailers.

Victoria

Emerald’s 10,000 square foot facility in Victoria, BC, is focused on processing and packaging of products for the adult-use market. It is also Emerald’s medicinal cannabis hub for customer relations, packaging and distribution. Victoria’s R&D lab also supports new product development initiatives.

Greater Vancouver

Emerald’s R&D facility in Greater Vancouver, BC, is explicitly designed, licensed and focused on the development of novel cannabinoid-based specialty products. The facility houses the new product development team with a mandate to create new intellectual property involving patents or trade secrets and is empowered to consider new concepts based on a spectrum of possibilities including formulation, delivery, bioavailability, and therapeutic capabilities, and to incorporate the attributes of “predictable action” and “Defined Dose™” to give consumers the benefit of discreet convenient consumption and reproducible outcomes in terms of rapid onset and offset of effects.

St. Eustache

Emerald’s vertically integrated 88,000 square feet indoor operation in Saint-Eustache, QC, is focused on producing premium craft cannabis products, notably under its Quebec-oriented Souvenir Brand. With standard cultivation and processing licenses, this operation is able to cultivate, sell and distribute packaged, branded cannabis products directly to provincial/territorial wholesalers and authorized private retailers.

Victoria

Emerald’s 10,000 square foot facility in Victoria, BC, is focused on processing and packaging of products for the adult-use market. It is also Emerald’s medicinal cannabis hub for customer relations, packaging and distribution. Victoria’s R&D lab also supports new product development initiatives.

Our Strategic Partners

OutsourceD production

TVC Black

EU Distribution

logo stenocare 1

Anticipated EU GMP Supply

MP-half1Kpx-color-1linea
Drop logo greenhouse texture

Stay updated

Join our investor newsletter to receive the latest news and updates from Emerald Health Therapeutics.

Unsubscribed by mistake? Please click here to resubscribe.

Moe Jiwan

Chief Operating Officer

Mr. Jiwan is a data driven business leader with over 20 years experience in strategic development , sales and operations management , e-commerce, and developing data and business intelligence solutions. Before joining Emerald, he served in senior leadership positions, including Chief Information Officer and Chief Customer Officer, for established cannabis and healthcare companies, including senior roles at TerrAscend Corp and Shopper’s Drug Mart. With a strong marketing and customer orientation, he has strongly focused on operational excellence and implementing processes to function faster, smarter, and leaner.

Rebecca Wong

Senior Vice President, Quality and Regulatory Affairs

Ms. Wong has over 30 years of quality and regulatory management experience in pharmaceutical and life science companies regulated to Canadian, US, European and international requirements. She has been responsible for establishing quality systems and ensuring regulatory compliance through all phases of product development from GPP, GLP, GCP, GMP for cannabis, pharmaceuticals, medical devices, combination products and biologicals. She was previously Executive Director of Quality Assurance at Novelion Therapeutics (formerly QLT Inc.) and worked for life science companies including MDS Nordion, Cangene Corporation, and Biomira Inc. Ms. Wong earned a B.Sc. (Microbiology) from the University of Alberta.

Jenn Hepburn

Chief Financial Officer

Ms. Hepburn has over a decade of experience in accounting and finance and is an experienced manager of privately and publicly traded manufacturing and mining businesses operating in Canada and the USA. Prior to joining Emerald, Ms. Hepburn was the Director of Finance and Administration at bioLytical Laboratories Inc., a medical diagnostics manufacturer. Before that, she held controller positions at junior gold and silver mining companies Northern Vertex Mining Corp., Kootenay Silver Inc. and Theia Resources Ltd. Ms. Hepburn earned a BBA from Simon Fraser University and her certification from the Certified Management Accountants of British Columbia.

RIAZ BANDALI

President & Chief Executive Officer

Mr. Bandali’s expertise in global operations, strategy development, driving innovation, M&A, and investment management has been developed over a 25-year career in the life sciences sector spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.

He holds an Advanced Management Program Degree from Harvard Business School, a Master of Business Administration from McGill University, and a Bachelor of Science from the University of British Columbia. He is an innovative business leader who has built strategic and operating plans that have resulted in rapid growth and significant profitability enhancement. He has managed businesses and operations with a global footprint and has led teams of over 900 people.

Mr. Bandali’s previous experience includes serving as President, Early Phase Clinical Services and Translational Science, Syneos Health; President, Early Stage Development, as well as Chief Innovation Officer, inVentiv Health Clinical; Senior Vice President, Strategy and Business Development, AB Sciex and Molecular Devices (part of Danaher Corporation); Senior Vice President, Strategy, Legal and Corporate Development, MDS Analytical Technologies; and Vice President and General Manager, Global Early Stage Development, MDS Pharma Services. He was also Venture Partner and Vice President at MDS Capital and has served on the boards of private and public companies.